EMBL, Life Sciences Partners lead €8m series-A for Luxendo

The capital injection follows an initial €6m capital injection led by LSP and EMBL and brings the total capital raised by the company to €8m.

As part of the funding round, EMBL's Stefan Herr and LSP's Joachim Rothe joined the company's board. According to a statement, the company will use the proceeds to drive the international sales of its devices by expanding its sales and marketing team.

Previous funding
Existing investors backed an initial capital injection of €6m as part of the series-A round in October 2015 to boost the company's spinout from the European Molecular Biology Laboratory.

Company
Founded in 2015 and headquartered in Heidelberg, Luxendo develops single-plane illumination microscopes for biomedical research, which allow scientists to observe living organisms for extended periods of time without them being adversely impacted by photo-toxicity and provide 3D imaging of the sample.

People
EMBL Ventures – Stefan Herr (managing director).
Life Science Partners – Joachim Rothe (partner).
Luxendo – Andreas Pfuhl (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Healthcare
• DACH
• Germany
• Life Science Partners
• Venture